Version 1
: Received: 16 October 2023 / Approved: 30 October 2023 / Online: 30 October 2023 (07:15:21 CET)
How to cite:
Lor, D.; Meyers, A.; Hubbard, L.; Peterson, J.; Lu, Y. Review of Post-discharge Thromboprophylaxis Practices and Outcomes in COVID-19 Patients. Preprints2023, 2023101835. https://doi.org/10.20944/preprints202310.1835.v1
Lor, D.; Meyers, A.; Hubbard, L.; Peterson, J.; Lu, Y. Review of Post-discharge Thromboprophylaxis Practices and Outcomes in COVID-19 Patients. Preprints 2023, 2023101835. https://doi.org/10.20944/preprints202310.1835.v1
Lor, D.; Meyers, A.; Hubbard, L.; Peterson, J.; Lu, Y. Review of Post-discharge Thromboprophylaxis Practices and Outcomes in COVID-19 Patients. Preprints2023, 2023101835. https://doi.org/10.20944/preprints202310.1835.v1
APA Style
Lor, D., Meyers, A., Hubbard, L., Peterson, J., & Lu, Y. (2023). Review of Post-discharge Thromboprophylaxis Practices and Outcomes in COVID-19 Patients. Preprints. https://doi.org/10.20944/preprints202310.1835.v1
Chicago/Turabian Style
Lor, D., Joel Peterson and Yun Lu. 2023 "Review of Post-discharge Thromboprophylaxis Practices and Outcomes in COVID-19 Patients" Preprints. https://doi.org/10.20944/preprints202310.1835.v1
Abstract
Patients hospitalized with COVID-19 are at a higher risk of thrombotic events following discharge, however the role of extended thromboprophylaxis remains controversial. The purpose of this study is to evaluate current extended post-discharge thromboprophylaxis practice and its outcomes.This study was a single-center, retrospective chart review of patients within Hennepin Healthcare hospitalized with COVID-19 from April 1st 2020 to December 31st 2021 with increased risk of thrombotic event based on D-dimer. The primary outcome was to describe current prescribing practices based on the number of patients who were eligible and received anticoagulants on discharge. Secondary outcomes included comparing the patient’s risk for thromboembolism based on a modified International Medical Prevention Registry on Venous Thromboembolism (IMPROVE-VTE) score to the current internal prescribing practice guideline, evaluating efficacy outcomes based on new thromboembolic events, and assessing safety of extended-thromboprophylaxis using the International Society of Thrombosis and Hemostasis criteria for major bleeding within 30 days of hospitalization discharge.Of 1984 patients who were hospitalized with COVID-19 infection, 961 patients were eligible to receive thromboprophylaxis at discharge, with a total of 191 patients who received anticoagulation according to the Hennepin Healthcare practice guideline. However, using the IMPROVE-VTE score, only 206 patients qualified for post-discharge thromboprophylaxis, and 63 total patients received anticoagulation. A new thromboembolic event occurred in 20 patients (5.8%) and 14 patients (4.1%) experienced major bleeding.The Hennepin Healthcare guideline for extended thromboprophylaxis at discharge encompassed more patients compared to the IMPROVE-VTE score. The incidence of a new thromboembolic event and major bleeding were low in both groups, although venous thrombotic events occurred more in thromboprophylaxis group than in patients who did not receive anticoagulation at discharge, more clinical data are needed for a conclusion.
Keywords
COVID 19; thrombosis, DOAC; Anticoagulant
Subject
Medicine and Pharmacology, Internal Medicine
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
